BRIGHT-4 trial: bivalirudin strikes back

Lancet. 2023 Apr 8;401(10383):1157-1158. doi: 10.1016/S0140-6736(23)00280-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Antithrombins* / therapeutic use
  • Heparin
  • Hirudins*
  • Humans
  • Peptide Fragments / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome

Substances

  • Anticoagulants
  • Antithrombins
  • bivalirudin
  • Heparin
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins